Allogene Therapeutics, Inc. - ALLO
Sector:
Healthcare
· Industry:
Biological Products, (No Diagnostic Substances)
Website:
No information yet
· Social:
No information yet
Company profile
Powered by TradingView
Quarter snapshot
Latest / Compare
Q4 2025
· Q3 2025
Value (USD)
Total reported value ($000)
$223M
QoQ value delta ($000)
+$27.59M
(+14.12%)
Implied price effect (QoQ)
+10.43%
Shares
Total shares
162,928,004
QoQ shares delta
+5,267,440
(+3.34%)
Total shares held by funds (by quarter)
Market chart (ALLO)
Powered by TradingView
Interactive chart by
TradingView.
Top holders (Q4 2025)
Top 25 only
Full list
| Manager | Value ($000) | Shares | % of 13F |
|---|---|---|---|
| PFIZER INC | 30,183 | 22,032,040 | 12.76% |
| TPG GP A, LLC | 25,641 | 18,716,306 | 0.95% |
| BlackRock, Inc. | 24,216 | 17,676,029 | 0.0% |
| CITADEL ADVISORS LLC | 16,726 | 12,208,820 | 0.0% |
| VANGUARD GROUP INC | 12,674 | 9,251,609 | 0.0% |
| PRIMECAP MANAGEMENT CO/CA/ | 11,151 | 8,139,840 | 0.01% |
| Patient Square Capital LP | 6,800 | 4,963,756 | 1.46% |
| GEODE CAPITAL MANAGEMENT, LLC | 5,388 | 3,932,910 | 0.0% |
| Frazier Life Sciences Management, L.P. | 5,300 | 3,868,750 | 0.14% |
| Woodline Partners LP | 4,795 | 3,500,499 | 0.02% |
| TWO SIGMA INVESTMENTS, LP | 4,690 | 3,423,441 | 0.01% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4,398 | 3,209,275 | 0.0% |
| Wildcat Capital Management, LLC | 4,001 | 2,920,787 | 2.93% |
| TWO SIGMA ADVISERS, LP | 3,959 | 2,890,200 | 0.01% |
| STATE STREET CORP | 3,783 | 2,761,400 | 0.0% |
| Kalehua Capital Management LLC | 3,488 | 2,546,129 | 3.45% |
| Candriam S.C.A. | 3,158 | 2,305,644 | 0.02% |
| GOLDMAN SACHS GROUP INC | 3,136 | 2,289,458 | 0.0% |
| RENAISSANCE TECHNOLOGIES LLC | 2,996 | 2,187,084 | 0.0% |
| JANE STREET GROUP, LLC | 2,979 | 2,174,683 | 0.0% |
| Aberdeen Group plc | 2,858 | 2,086,332 | 0.0% |
| MILLENNIUM MANAGEMENT LLC | 2,522 | 1,841,307 | 0.0% |
| FMR LLC | 1,980 | 1,445,761 | 0.0% |
| AQR CAPITAL MANAGEMENT LLC | 1,958 | 1,429,247 | 0.0% |
| UBS Group AG | 1,903 | 1,389,593 | 0.0% |